Qiagen에 대한 매도 수량은 투자자에게 Qiagen의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Qiagen (NYSE:QGEN) 주식, 공매도 수량 보고

Qiagen

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).

Qiagen NV

Qiagen N.V.

Analyst Color

Earnings

Equities

Large Cap

Mid Cap

Tech

ETFs

AMGN

AVGO

AZEK

DELL

Janus Henderson Group plc Ordinary Shares

KVYO

MNDY

NVDA

QGEN

SNOW

TOST

UPST

3분기 실적 시즌이 다가오면서, 골드만삭스는 투자자들이 재무 실적을 통해 수익을 올릴 수 있는 주요 주식 기회를 식별한 노트를 발표했다. 애널리스트 존 마샬(John Marshall)과 그의 팀은 목요일에 18개의 주식이 실적 상향 조정의 혜택을 받을 가능성이 있고, 7개의 주식은 하향 조정의 영향을 받을 가능성이 있다고 강조했다.

이번 실적 시즌에는 매수할 주식 18개, 매도할 주식 7개: 골드만삭스는 올해를 &#39;주식 선택자의 해&#39;

On November 13, 2024, Syros Pharmaceuticals, Inc. (the "Company") gave notice to QIAGEN Manchester Limited ("QIAGEN") of its election to terminate the Master Collaboration Agreement dated March 7, 2022 (the "Agreement") relating to the development and commercialization of an assay as a companion diagnostic test for use with tamibarotene as a result of the failure of the Company's SELECT-MDS-1 Phase3 trial evaluating tamibarotene to meet its primary endpoint of complete response rate, which was previously disclosed on the Company's Current Report on Form 8-Kfiled with the U.S. Securities and Exchange Commission (the "SEC") on November 13, 2024. The termination will be effective 90 days following such notice.

News

SYRS

Syros Pharmaceuticals Gave Notice To Qiagen Manchester Limited Of Its Election To Terminate The Master Collaboration Agreement Dated March 7, 2022

Contracts

QIAGEN Collaborates With McGill University On Microbiome Research; Terms Not Disclosed

QIAGEN has reaffirmed its FY 2024 sales outlook for at least $1.985 billion CER based on the solid core business performance in the first nine months of the year. The outlook for adjusted diluted EPS has been increased to at least $2.19 CER (previously $2.10 CER at start of 2024), while the adjusted operating income margin target has been reaffirmed for at least 28.5% compared to 26.9% in 2023.

Guidance

QIAGEN Reaffirms FY24 Sales Of At Least $1.985B Vs $1.98B Est.; Increases EPS Guidance From $2.10 CER To At Least $2.19 CER Vs $2.15 Est.

Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.54 by 5.56 percent. This is a 14 percent increase over earnings of $0.50 per share from the same period last year. The company reported quarterly sales of $502.00 million which beat the analyst consensus estimate of $491.75 million by 2.09 percent. This is a 5.49 percent increase over sales of $475.89 million the same period last year.

Earnings Beats

Qiagen Q3 Adj $0.57 Beats $0.54 Estimate, Sales $502.00M Beat $491.75M Estimate

QIAGEN Gains FDA Clearance For Rapid QIAstat-Dx Meningitis/Encephalitis Panel, Boosting Emergency Diagnostics

QIAGEN Secures FDA Clearance For Qiastat-Dx Mini Panel, Enhancing Precision In Outpatient Respiratory Care

HSBC analyst Shubhangi Gupta downgrades Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) from Buy to Hold.

Downgrades

Analyst Ratings

HSBC Downgrades Qiagen to Hold

As the third-quarter earnings season approaches, Goldman Sachs has issued a note identifying key stock opportunities for investors looking to profit <a href="https://www.benzinga.com/news/earnings/24/10/41255250/banks-gear-up-for-earnings-season-15-top-stock-picks-including-citigroup-morgan-stanley-and-truist">from financial results.</a>
Analyst John Marshall and his team shared their insights on Thursday, highlighting 18 stocks that could benefit from upward earnings revisions and seven stocks likely to face downward revisions.
<h3 class="wp-block-heading">The &#8216;Stock Picker&#8217;s Year&#8217;: 10% Upside In S&amp;P 500</h3>
Goldman Sachs analysts call 2024 "the year of the stock picker," emphasizing the importance of selective investing in a volatile earnings environment.
According to the investment bank&#8217;s latest projections, the average S&amp;P 500 stock could see a 10% upside over the next 12 months. 
"We see relief rally potential," Marshall stated in his note. "Directional positioning in the options market is balanced, a much better set-up than this time last quarter."
The analysts also observed that activity in options markets, both from hedge funds and retail traders, has decreased recently, signaling a "wait-and-see" approach as investors prepare for third-quarter earnings reports and the upcoming U.S. elections.
<h3 class="wp-block-heading">Earnings Season Volatility Remains Elevated</h3>
Goldman Sachs highlighted that single-stock volatility surrounding earnings events remains at a 14-year high. 
This trend, driven by critical market debates on topics like artificial intelligence, interest rates, and the upcoming election, is expected to continue through the remainder of the year.
&#8220;We expect earnings day moves to remain elevated as most of the key debates for the market have winners and losers in the equity space,&#8221; the note added. 
With this heightened volatility, the firm continues to recommend options-based strategies, advising investors to consider buying options ahead of earnings events and selling options between earnings periods to capitalize on price movements.
<h3 class="wp-block-heading">18 Stocks Goldman Sachs Is Bullish On For Third-Quarter Earnings</h3>
Goldman Sachs&#8217; analysts have identified 18 stocks they believe are primed for upside as earnings revisions could be favorable. These stocks span a variety of sectors, from energy and financials to healthcare and technology.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Sector</th>
<th>Earnings Date (e)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>)</td>
<td>Discretionary</td>
<td>Nov. 15</td>
</tr>
<tr>
<td>Permian Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PR#NYSE">PR</a>)</td>
<td>Energy</td>
<td>Nov. 7</td>
</tr>
<tr>
<td>Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>)</td>
<td>Financials</td>
<td>Oct. 15</td>
</tr>
<tr>
<td>Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>)</td>
<td>Financials</td>
<td>Oct. 16</td>
</tr>
<tr>
<td>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>Healthcare</td>
<td>Oct. 30</td>
</tr>
<tr>
<td>Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>)</td>
<td>Healthcare</td>
<td>Oct. 23</td>
</tr>
<tr>
<td>Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>Healthcare</td>
<td>Oct. 31</td>
</tr>
<tr>
<td>Qiagen NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>)</td>
<td>Healthcare</td>
<td>Oct. 30</td>
</tr>
<tr>
<td>AZEK Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>)</td>
<td>Industrials</td>
<td>Nov. 29</td>
</tr>
<tr>
<td>ADT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADT#NYSE">ADT</a>)</td>
<td>TMT</td>
<td>Nov. 1</td>
</tr>
<tr>
<td>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</td>
<td>TMT</td>
<td>Dec. 6</td>
</tr>
<tr>
<td>Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)</td>
<td>TMT</td>
<td>Nov. 25</td>
</tr>
<tr>
<td>Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>)</td>
<td>TMT</td>
<td>Nov. 7</td>
</tr>
<tr>
<td>Monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>)</td>
<td>TMT</td>
<td>Nov. 13</td>
</tr>
<tr>
<td>Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>TMT</td>
<td>Nov. 21</td>
</tr>
<tr>
<td>Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>)</td>
<td>TMT</td>
<td>Nov. 29</td>
</tr>
<tr>
<td>Toast Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>)</td>
<td>TMT</td>
<td>Nov. 7</td>
</tr>
<tr>
<td>Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>)</td>
<td>Utilities</td>
<td>Nov. 4</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">7 Stocks Goldman Sachs Is Bearish On For Third-Quarter Earnings</h3>
In contrast, the investment bank has identified seven stocks that they expect to face downward earnings revisions in the third quarter, advising investors to exercise caution.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Sector</th>
<th>Earnings Date (e)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Choice Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHH#NYSE">CHH</a>)</td>
<td>Discretionary</td>
<td>Nov. 7</td>
</tr>
<tr>
<td>Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CQP#NYSE">CQP</a>)</td>
<td>Energy</td>
<td>Nov. 1</td>
</tr>
<tr>
<td>Janus Henderson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>)</td>
<td>Financials</td>
<td>Oct. 31</td>
</tr>
<tr>
<td>LyondellBasell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>)</td>
<td>Materials</td>
<td>Nov. 1</td>
</tr>
<tr>
<td>Clorox Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>)</td>
<td>Staples</td>
<td>Nov. 1</td>
</tr>
<tr>
<td>Kraft Heinz Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>)</td>
<td>Staples</td>
<td>Oct. 30</td>
</tr>
<tr>
<td>Upstart Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>)</td>
<td>TMT</td>
<td>Nov. 7</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41278012/feds-goolsbee-downplays-inflation-uptick-economists-hold-steady-on-november-rate-in">Fed&#8217;s Goolsbee Downplays Inflation Uptick, Economists Hold Steady On November Rate Interest Rate Cut Call</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'

These updates &ndash; designed for use on the QIAsymphony and EZ2 Connect instruments &ndash; are designed to enable research and molecular diagnostics laboratories to efficiently improve results when processing larger sample volumes that are crucial for oncology research and diagnostics.
The upgrades add to the PAXgene Urine Liquid Biopsy Set recently launched by PreAnalytiX, QIAGEN&#39;s joint venture with BD. The new set, which will be commercialized by QIAGEN, enables reliable analysis of cfDNA from urine more than ever before.

QIAGEN Reveals Key Updates To Its Sample Technologies Solutions For Non-Invasive Liquid Biopsy Applications

QIAGEN N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA)))) today announced the launch of the QIAcuityDx Digital PCR System, a pivotal addition to its digital PCR portfolio now expanding into clinical diagnostics. The instrument and accessories are 510(k) exempt in the U.S. and IVDR-certified for diagnostic use in Europe.
QIAcuityDx streamlines clinical testing by providing highly precise, absolute quantitation of target DNA and RNA, supporting applications with less invasive liquid biopsies. These capabilities make it an ideal tool for monitoring cancer progression, complementing routine cancer diagnoses, which are typically performed using Next Generation Sequencing (NGS).
QIAGEN is rapidly expanding the application menu available on QIAcuityDx-System, with a new BCR::ABL assay for oncohematology planned for FDA submission in 2025. The platform also provides immediate access to QIAGEN's full portfolio of research-use products and applications via its GeneGlobe platform. QIAGEN has already signed three partnerships with pharmaceutical companies to develop companion diagnostics on the QIAcuityDx, moving digital PCR into precision medicine. In addition, QIAGEN plans to further enhance the future assay portfolio by collaborating with third parties, who will develop their own assays for the platform.

Biotech

General

QIAGEN Launches QIAcuityDx Digital PCR System For Clinical Testing In Oncology

QIAGEN Receives European IVDR Certification For QIAstat-Dx Syndromic Testing Instruments And Assays

QIAGEN And BD Joint Venture, PreAnalytiX, Launches Solution For Liquid Biopsy From Urine Samples

The multi-year agreement between QIAGEN&#39;s subsidiary Verogen and Bode extends the long-standing partnership of two leading companies in forensic investigative genetic genealogy (FIGG) to further accelerate the use of GEDmatch PRO in law enforcement and identification of human remains.&nbsp;
As part of the partnership, Bode will manage all commercial transactions for GEDmatch PRO globally, while QIAGEN will continue to develop new features with input from Bode&#39;s genealogy experts. Bode will maintain the highest level of data security as GEDmatch PRO users will continue to own their case data and no additional identifying information will be shared with Bode.

QIAGEN, Bode Technology Enter Multi-year Agreement For GEDmatch PRO Genealogy Database

QIAGEN Expands QIAcuity Digital PCR Offering With Over 100 New Assays Via GeneGlobe Platform, Supporting Cancer Research, Genetic Disorders, Infectious Disease Surveillance, And Environmental Monitoring

QIAGEN N.V.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/qgen#NYSE">QGEN</a>) announced the expansion of its strategic partnership with Bio-Manguinhos/Fiocruz, a leading vaccines and diagnostics supplier to the Brazilian Ministry of Health. Initiated in 2009, the expanded collaboration allows Bio-Manguinhos to launch an advanced PCR (Polymerase Chain Reaction)-based molecular screening platform to detect malaria alongside HIV, hepatitis B and C virus, a capability previously unavailable in Brazil&#39;s blood donation program. The recent development will also support epidemiological surveillance of Brazil&#39;s ongoing dengue epidemic by composing dengue molecular kits based on unique collaborative chemistry.
Following the news, shares of QGEN declined 0.6% to $45.57 at yesterday&#39;s close. However, the company is accelerating the introduction of cutting-edge products and capabilities to the market through tailored OEM (Original Equipment Manufacturer) offerings and extensive support for companies in the life sciences research, biotechnology and diagnostics sectors. Hence, we expect the market sentiment to remain positive around this news.
<h2>More on QIAGEN&#39;s Expanded Collaboration</h2>
Brazil&#39;s national blood screening program was launched in 2010, the largest blood donation safety initiative in its history. The advanced Brazilian Nucleic Acid Test (NAT Plus) platform, which utilizes QIAGEN&#39;s PCR reagents, was recently rolled out as part of the program. The latest advancement improves transfusional safety by detecting malaria and closing the &quot;diagnostic window&quot; between the time of infection and laboratory diagnosis. Since 2009, QIAGEN and Bio-Manguinhos have been partnering to equip the national blood screening program with advanced molecular testing solutions.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/77/77671.jpg?v=403415906" />
Image Source: Zacks Investment Research
Presently, the NAT Plus platform is operational in 30 laboratories and is critical to safeguarding blood supplies in regions where these diseases are not endemic. It supports health surveillance within the blood transfusion system, engaging over 300 trained professionals across 14 chemotherapy centers and processing 3.5 million samples annually. QIAGEN will supply critical molecular biology technologies, custom solutions and comprehensive training to facilitate Brazil&#39;s public health initiative. Under the terms of this agreement, the company&#39;s solutions will be included in the screening kits and private labeled under the Bio-Manguinhos&#39; brand.
The collaboration also emphasizes the pivotal role of QIAGEN&#39;s Strategic Partnerships and OEM Division, supporting more than 400 partners globally.
<h2>Industry Prospects Favoring QGEN</h2>
A report from the SkyQuest Technology Group valued the global PCR molecular diagnostics market at $17.8 billion in 2021, forecasted to witness a compound annual growth rate of 12.8% through 2030. The market is a fast-growing sector, driven by the need for accurate and timely diagnostic testing. The rising incidences of infectious diseases, genetic disorders and cancer create a substantial market opportunity for PCR molecular diagnostics. Furthermore, the growing awareness and adoption of precision medicine approaches further contribute to the market&#39;s potential for targeted therapies and personalized treatment regimens.
<h2>QIAGEN&#39;s Recent Developments</h2>
Last week, QIAGEN teamed up with Eli Lilly and Company to support the development of a QIAstat-Dx in-vitro diagnostic to detect APOE (apolipoprotein E) genotypes in the diagnosis of Alzheimer&#39;s disease. The panel will be integrated with QIAGEN&#39;s multiplex testing platform QIAstat-Dx, marking the first publicly disclosed collaboration for a clinical application of the system in neurodegenerative diseases and adding to two more collaborations for diagnostics development programs with other companies.
<h2>QGEN&#39;s Price Performance</h2>
In the past year, QGEN shares have gained 6% against the industry&#39;s 2.2% fall.
<h2>QGEN&#39;s Zacks Rank and Key Picks</h2>
QIAGEN currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Boston Scientific (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>), AxoGen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>) and SiBone (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sibn#NASDAQ">SIBN</a>), each carrying a Zacks Rank #2 (Buy) at present.
Boston Scientific&#39;s shares have gained 58.4% in the past year. Estimates for the company&#39;s earnings per share have remained constant at $2.40 in 2024 and $2.71 in 2025 in the past 30 days. BSX&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.2%. In the last reported quarter, it posted an earnings surprise of 6.9%.
Estimates for AxoGen&#39;s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 145% in the past year compared with the industry&#39;s growth of 15.5%. AXGN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.
Estimates for SiBone&#39;s 2024 loss per share have remained constant at 89 cents in the past 30 days. Shares of the company have dropped 30.4% in the past year against the industry&#39;s 15.5% growth. SIBN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.4%. In the last reported quarter, it delivered an earnings surprise of 15.4%.
<a href="https://www.zacks.com/stock/news/2335917/can-qgen-stock-gain-from-the-expanded-bio-manguinhos-fiocruz-alliance?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2335917">To read this article on Zacks.com click here.</a>

Offerings

Small Cap

Markets

Trading Ideas

AXGN

SIBN

Can QGEN Stock Gain From the Expanded Bio-Manguinhos/Fiocruz Alliance?

The partnership, initiated in 2009, supported Bio-Manguinhos/Fiocruz with reagents and instruments for testing samples for HIV and hepatitis C virus.&nbsp;
With the expansion of this collaboration, Bio-Manguinhos is now able to launch an advanced PCR-based molecular screening platform to detect malaria alongside HIV, hepatitis B and C virus (HCV and HBV), a capability previously unavailable in Brazil&#39;s blood donation program. It also supports epidemiological surveillance of Brazil&#39;s ongoing dengue epidemic by composing Bio-Manguinhos/Fiocruz dengue&nbsp;molecular kits based on unique chemistry developed by QIAGEN and Bio-Manguinhos/Fiocruz. QIAGEN will supply critical molecular biology technologies, custom solutions, and comprehensive training to facilitate Brazil&#39;s public health initiative.

QIAGEN Expands Strategic Partnership With Bio-Manguinhos/Fiocruz

This collaboration represents a significant milestone as the QIAstat-Dx panel would be the first commercially available IVD for APOE genotyping.

QIAGEN Enters Collaboration With Eli Lilly To Support Development Of QIAstat-Dx In-vitro Diagnostic To Detect APOE Genotypes Which Can Play Role In Diagnosis Of Alzheimer's Disease; No Terms Disclosed

QIAGEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA)))) today announced the expansion of its Master Collaboration Agreement with AstraZeneca to develop and commercialize companion diagnostics (CDx) for AstraZeneca's future therapies being developed to address chronic diseases.
Under the agreement, QIAGEN will develop and validate a genotyping assay using QIAGEN's syndromic testing platform QIAstat-Dx. The test will enable specialty care providers to potentially perform genotyping whilst patients are undergoing routine clinical examination, thus enabling fast decision making for potential suitability for AstraZeneca's genomically targeted medicines.

QIAGEN Expands Master Collaboration Agreement With AstraZeneca's Future Therapies To Develop And Validate A Genotyping Assay Using Co's Syndromic Testing Platform QIAstat-Dx

Baird analyst Catherine Schulte maintains Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) with a Outperform and raises the price target from $49 to $52.

Price Target

Baird Maintains Outperform on Qiagen, Raises Price Target to $52

QIAGEN has updated its FY 2024 outlook based on the solid core business performance in the first half of the year, which was about $15 million CER above guidance, as well as the decision to phase out the NeuMoDx clinical PCR system. As a result, total net sales are expected to be at least $1.985 billion CER and includes a $30 million CER adjustment in expected NeuMoDx sales for 2024.
The outlook for adjusted diluted EPS has been increased to at least $2.16 CER, while the adjusted operating income margin target is for at least 28.5% compared to 26.9% in 2023.

Qiagen Sees FY24 EPS $2.16 Vs $2.12 Est.; Revenue $1.985B Vs $2B Est.

Qiagen N.V. (QGEN) Q3 2024 Earnings Call Transcript

Qiagen (QGEN) has released an update. Qiagen has reported its financial results for the third quarter of 2024, showing an increase in total assets ...

Qiagen's Financial Growth and Rising Debt in Q3 2024

Qiagen (QGEN) has released an update. Qiagen reported solid growth in Q3 2024, with net sales reaching $502 million, surpassing expectations. The c...

Qiagen's Q3 2024 Results Exceed Expectations, Boost Outlook

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vigil Neuroscience Inc (VIGL – Research Report), Qiagen (QGEN – R...

Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL), Qiagen (QGEN) and LifeMD (LFMD)

Morgan Stanley raised the firm's price target on Qiagen (QGEN) to EUR 46 from EUR 45 and keeps an Overweight rating on the shares. Published first ...

Qiagen price target raised to EUR 46 from EUR 45 at Morgan Stanley

Qiagen (QGEN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 7. Analyst Catherine Ramsey Schu...

Qiagen's Strong Performance and Strategic Initiatives Justify Buy Rating

UBS analyst Dan Leonard maintained a Hold rating on Qiagen (QGEN – Research Report) today. The company's shares closed last Friday at $43.76. Accor...

UBS Remains a Hold on Qiagen (QGEN)

Qiagen (QGEN) announced a collaboration with the McGill University Centre for Microbiome Research to support microbiome research activities and out...

Qiagen enters three-year partnership with McGill University

Catalyst Watch: Nvidia earnings, Microsoft Ignite, crypto confidence, and P&G event

Morgan Stanley lists hedge funds' largest Q3 ownership increases in Russell 1000 stocks

ABIT

ACHC

ASAN

BIDU

BILL

BKKT

BRBR

BRPHF

BTBT

CAVA

CHRW

CIVI

CRNC

CRWS

CTLT

EDIT

FCEL

FTNT

FWONA

GEHC

HNST

HYMTF

INOD

INTU

IONS

JACK

JAKK

LFMD

LITE

MARA

MRUS

MSTR

MTCH

MVIS

NAPA

ORCL

PANW

PCOR

PYCR

QUAD

RIOT

ROST

RVTY

SAVE

SOLV

STLA

STNG

TCOM

TRMD

USPH

VIGL

VLKAF

WING

XPEV

Press Releases

QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays

QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology

Neogen Announces the Appointment of New Board Member

Global TB Summit 2024: QIAGEN leads the charge as tuberculosis reemerges as a leading infectious killer

QIAGEN N.V. to release results for Q3 2024 and hold webcast

QIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applications

QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment

QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics

QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook

Comments

Qiagen

매도 수량

Qiagen (NYSE:QGEN) 주식, 공매도 수량 보고

뉴스

파트너 / 기고자

벤징가 글로벌